Celsion Corp
Slēgts
0
Pārskats
Akcijas cenas izmaiņa
24h
Min
Max
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +675.74% upside |
Celsion Corp Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
Celsion Corp Prognoze
Cenas mērķis
By TipRanks
675.74% augšup
Prognoze 12 mēnešiem
Vidējais 15.67 USD 675.74%
Augstākais 25 USD
Zemākais 10 USD
Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Celsion Corp — pēdējo 3 mēnešu laikā.
Finanšu rādītāji
$
Par Celsion Corp
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
